Consensus Twist Bioscience Corporation

Equities

TWST

US90184D1000

Market Closed - Nasdaq Other stock markets 21:00:00 26/04/2024 BST			5-day change	1st Jan Change
31.54 ^USD	+1.48%		+12.84%	-14.43%

03-28	Twist Bioscience Corporation Launches Pangenome Spike-in Exome Panel to Enable Advancement of Research for Diverse Populations	CI
03-12	Transcript : Twist Bioscience Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM

Evolution of the average Target Price on Twist Bioscience Corporation

Price target over the last 5 years

History of analyst recommendation changes

5ff0f5d.Zs2C9w45VSDBfAASZqKpoB26L_Nz1wjhSJxik2iIsWg.U4exxTt6B1euFUpjM-ybkCWXH6oxtT-zBsVVojz5iSAD4OCbeU40TLkKOA~cf33336a7ddaf6e1a4911f704d17d32e

Analyst Recommendations on Twist Bioscience Corporation

Scotiabank Adjusts Twist Bioscience's Price Target to $43 From $30, Maintains Sector Outperform Rating	02-05	MT
Barclays Raises Price Target on Twist Bioscience to $45 From $30, Keeps Overweight Rating	01-25	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Raises Price Target to $45 From $25	01-18	MT
Goldman Sachs Upgrades Twist Bioscience to Buy From Neutral, Price Target is $45	01-17	MT
Evercore ISI Raises Twist Bioscience Price Target to $32 From $26, Maintains Outperform Rating	11-17	MT
Berenberg Initiates Coverage on Twist Bioscience with Buy Rating, $27 Price Target	27/09/23	MT
Barclays Adjusts Price Target on Twist Bioscience to $26 From $20, Keeps Overweight Rating	07/08/23	MT
Barclays Adjusts Twist Bioscience Price Target to $26 From $20, Maintains Overweight Rating	07/08/23	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $18, Maintains Neutral Rating	13/07/23	MT
Barclays Adjusts Price Target on Twist Bioscience to $20 From $32, Maintains Overweight Rating	08/05/23	MT
Baird Adjusts Twist Bioscience Price Target to $18 From $29, Maintains Outperform Rating	08/05/23	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $20 From $43, Maintains Neutral Rating	18/04/23	MT
Goldman Sachs Adjusts Price Target on Twist Bioscience to $43 From $50, Maintains Neutral Rating	06/02/23	MT
Barclays Adjusts Price Target on Twist Bioscience to $32 From $37, Maintains Overweight Rating	06/02/23	MT
Baird Adjusts Price Target on Twist Bioscience to $29 From $33, Maintains Outperform Rating	06/02/23	MT
Barclays Adjusts Price Target on Twist Bioscience to $37 From $43, Maintains Overweight Rating	30/01/23	MT
Scotiabank Initiates Twist Bioscience at Outperform Rating With $33 Price Target	05/01/23	MT
Scotiabank Initiates Twist Bioscience at Sector Outperform With $33 Price Target	05/01/23	MT
Evercore ISI Upgrades Twist Bioscience to Outperform From In Line, Adjusts Price Target to $36 From $28	03/01/23	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $30 From $45, Keeps Market Perform Rating	21/11/22	MT
Baird Adjusts Price Target on Twist Bioscience to $33 From $56, Maintains Outperform Rating	21/11/22	MT
Barclays Trims Price Target on Twist Bioscience to $43 From $45, Maintains Overweight Rating	21/11/22	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $45 From $50, Maintains Market Perform Rating	07/10/22	MT
Barclays Adjusts Price Target on Twist Bioscience to $45 From $55, Reiterates Overweight Rating	06/10/22	MT
SVB Securities Adjusts Twist Bioscience's Price Target to $50 from $45, Maintains Market Perform Rating	08/08/22	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

31.54 USD

Average target price

40.25 USD

Spread / Average Target

+27.62%

High Price Target

48 USD

Spread / Highest target

+52.19%

Low Price Target

25 USD

Spread / Lowest Target

-20.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Twist Bioscience Corporation

Scotiabank
Barclays
Goldman Sachs
Evercore ISI
Berenberg Bank
Baird
SVB Securities LLC
JPMorgan Chase
SVB Leerink
William Blair & Co.
Piper Sandler
J.P. Morgan Chase

Ratings for Twist Bioscience Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar